Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TG103 in Type 2 Diabetes
NCT04790006Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Apr 2021
- Primary completion
- Mar 2022
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 1, randomised, double-blind trial of GX-G6 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Incidence and severity of adverse events at 15 weeks. Status: unknown.
02
Drugs
GX-G6
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04790006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04790006.